Medical Oncology

Richard Francis Riedel, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept of Medicine, 25179 Morris Bldg, Durham, NC 27710
Phone (919) 681-8031
Email address richard.riedel@duke.edu

Novel therapies for soft tissue and bone sarcomas

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2007
  • Fellow in Hematology-Oncology, Medicine, Duke University, 2003 - 2004
  • Resident in Medicine, Medicine, Duke University, 2000 - 2003
  • M.D., Thomas Jefferson University, 2000

Grants

Publications

Joseph, Cissimol P., Sarah N. Abaricia, Michelle A. Angelis, Kathleen Polson, Robin L. Jones, Yoon-Koo Kang, Richard F. Riedel, et al. “Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.” Oncologist, December 10, 2020. https://doi.org/10.1002/onco.13632.

PMID
33301227
Full Text

Mehren, Margaret von, John M. Kane, Marilyn M. Bui, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, et al. “NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.” J Natl Compr Canc Netw 18, no. 12 (December 2, 2020): 1604–12. https://doi.org/10.6004/jnccn.2020.0058.

PMID
33285515
Full Text

Riedel, Richard F., Karla V. Ballman, Yao Lu, Steven Attia, Elizabeth T. Loggers, Kristen N. Ganjoo, Michael B. Livingston, et al. “A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.” Oncologist 25, no. 11 (November 2020): e1655–62. https://doi.org/10.1634/theoncologist.2020-0679.

PMID
32701199
Full Text

Ludwig, J. A., N. Federman, P. Anderson, M. E. Macy, L. E. Davis, R. F. Riedel, J. A. Muscal, et al. “1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma.” In Annals of Oncology, 31:S972–S972. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.1846.

Full Text

Chawla, Sant P., Sanjay Goel, Warren Chow, Fadi Braiteh, Arun S. Singh, Juneko E Grilley Olson, Atsushi Osada, Iulian Bobe, and Richard F. Riedel. “A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma.” Clin Cancer Res 26, no. 16 (August 15, 2020): 4225–32. https://doi.org/10.1158/1078-0432.CCR-20-0591.

PMID
32381487
Full Text

Hendrix, Cristina C., Doreen Matters, Tamara Griffin, Heather Batchelder, Patricia Kramer, Judy R. Prewitt, Loretta Matters, et al. “Academic-Practice Partnership for Caregiver Training and Support: The Duke Elder Family/Caregiver Training (DEFT) Center.” N C Med J 81, no. 4 (July 2020): 221–27. https://doi.org/10.18043/ncm.81.4.221.

PMID
32641453
Full Text

Scheffler, Matthias, Alessandra Holzem, Anna Kron, Lucia Nogova, Michaela A. Ihle, Cornelia von Levetzow, Jana Fassunke, et al. “Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.” Lung Cancer (Amsterdam, Netherlands) 144 (June 2020): 40–48. https://doi.org/10.1016/j.lungcan.2020.04.020.

PMID
32361034
Full Text

Ingham, Matthew, Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark Andrew Dickson, Richard F. Riedel, Steven Attia, et al. “A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Wagner, Andrew J., Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian Andrew Van Tine, Rashmi Chugh, Lee D. Cranmer, et al. “Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Keung, Emily Z., Melissa Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales, Vanessa Bolejack, Brian A. Van Tine, et al. “Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1258–66. https://doi.org/10.1158/1078-0432.CCR-19-1824.

PMID
31900276
Full Text

Pages